Fig. S7.

Dual cediranib+MEDI3617 therapy has no effect on granulocyte or T-cell recruitment to Gl261 tumors. Gl261 tumors were collected from mice treated with control (n = 7), MEDI3617 (n = 7), cediranib (n = 7), or dual cediranib+MEDI3617 therapy (n = 8) at day 10 after the beginning of treatment. After disassociation, the resulting cell suspensions were stained with CD45, Gr1, CD4, and CD8 antibodies for flow cytometric analysis of myeloid and lymphoid populations within the tumors. There was no difference among the treatment groups in the percentages of CD45⁺ cells (A), CD45⁺Gr1⁺ granulocytes (B), CD4⁺ T lymphocytes (C), or CD8⁺ T lymphocytes (D). Error bars represent the SEM.